Proliferative Effects of Erythropoietin on Human Endometrium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-23

Study Completion Date

2018-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to assess the proliferative effects of erythropoetin on human endometrium tissue by measuring the endometrial thickness, uterine artery and subendometrial blood flow in postmenopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis

NCT04287205

Endometriosis Sexual Dysfunction

COMPLETED NA

Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding

NCT03351673

Endometrial Disorder

UNKNOWN NA

Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects

NCT02406690

Endometrial Dysfunction

COMPLETED

Assessment of the Uterus Using Ultrasonographic Elastography in Women with Dysmenorrhea

NCT06606834

Primary Dysmenorrhea

NOT_YET_RECRUITING

Effects of Varied Estrogen Doses on Endometrial Receptivity

NCT02458404

Luteal Phase Defect

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 postmenopausal women who are planned to treat with erythropoietin alpha for their renal conditions will be included to the study. Sample size was calculated with proper power analysis with accepting the difference of 1 mm in endometrial thickness as a significant change. After the informed consent, endometrial thickness (mm), uterine artery and subendometrial blood flow by doppler ultrasonography (RI, S/D) will be measured. Same measurements will be repeated on the 3rd day and 30th day. Patients' age, BMI, co-morbidities, administered erythropoietin doses will be noted. No adverse effect is expected with regard to the ultrasonographic examination. Date of the patients who do not attend for the appointments for repetitive examinations and uninterpretable doppler variables due to the atrophic uterus will be noted as the missing data and will be excluded from the study. Proper statistical analysis will be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Endometrial Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erythropoietin

Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.

Erythropoietin

Intervention Type DRUG

Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erythropoietin

Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically condition with need for erythropoietin treatment such as anemia due to the renal failure or the need for hemodialysis.
* Must be in postmenopausal period

Exclusion Criteria

* Patients with any type of malignancy
* Existence of any intracavitary mass which may affect endometrial thickness or blood flow such as endometrial polyps, myomas, intracavitary fluid etc.
* Intrauterine device
* Being on Hormon replacement therapy
* Hysterectomized patients

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No